Advertisement

Bismuth and Helicobacter pylori

  • P. Malfertheiner
  • M. Nilius
  • U. Kreusel
Conference paper

Abstract

The first preparative method in making bismuth salts accessible for therapeutic purposes goes back to Georg Agricola, in the 16th century [1]. In 1786 Odier first administered “magisterium bismuti” (bismuth subnitrate) as a “safe, infallible remedy against gastric spasm”, in a dose of 24 g per day [2]. The nineteenth century brought the wide use of bismuth compounds for the treatment of syphilis. In the 1850s, treatment of dispeptic symptoms with bismuth compounds was made popular by Chambers in England and Kussmaul in Germany, administering bismuth subnitrate in doses up to 400 g [2].

Keywords

Pylorus Infection Bismuth Compound Bismuth Subcitrate Colloidal Bismuth Subcitrate Bismuth Salt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Von Lippmann EO (1930) Die Geschichte des Wismuts zwischen 1400 und 1800. Springer, Berlin Heidelberg New YorkGoogle Scholar
  2. 2.
    Hotz J (1990) Die Historie der Wismutbehandlung. In: Malfertheiner P, Holz J, Ditschuneit H (eds) Wismut: Therapiekonzept bei Helicobacter pylori, Gastritis und Ulkuskrankheit. Zuckschwerdt, MunichGoogle Scholar
  3. 3.
    Morrow AW (1973) Request for reports: adverse reactions with bismuth subgallate. Med J Aust 60:912Google Scholar
  4. 4.
    Burns R, Thomas DW, Barron VJ (1974) Reversible encephalopathy possible associated with bismuth subgallate ingestion. BMJ 1:220–223PubMedCrossRefGoogle Scholar
  5. 5.
    Buge A, Rancurel G, Poisson M, Dechy H (1974) Encephalopathies aiguës au cours des traitements oraux par les sels de bismuth. Nouv Presse Med 3:2315–2320PubMedGoogle Scholar
  6. 6.
    Bader JP (1987) The safety profile of De-Nol. Digestion 37 [Suppl 2]: 53–59PubMedCrossRefGoogle Scholar
  7. 7.
    Greenwood NN, Earnshaw A (1984) Chemistry of the elements. Pergamon, OxfordGoogle Scholar
  8. 8.
    Marshall BJ (1991) The use of bismuth in gastroenterology. Am J Gastroenterol 86:16–25PubMedGoogle Scholar
  9. 9.
    Herrmann WA, Herdtweck E, Pajdla L (1991) Colloidal bisuth subcitrate (CBS) isolation and structural characterization of the active substance against Hehcobacter pylori, a causal factor of gastric diseases. Inorg Chem 30:2579–2581CrossRefGoogle Scholar
  10. 10.
    Pearson RG (1986) Acids and bases. J Am Chem Soc 85:3563Google Scholar
  11. 11.
    Konturek SJ, Radecki T, Piastucki I, Drozdowicz D (1986) Advances in the understanding of the mechanism of cytoroprotective action by colloidal bismuth subcitrate. Scand J Gastroenterol 21 [Suppl]: 6–10CrossRefGoogle Scholar
  12. 12.
    Coghill SB, Hopwood D, McPherson S, Hislop S (1983) The ultrastructural localisation of De-Nol (colloidal tripotassium dicitrate bismuthate TDB) in the upper gstrointestinal track of man and rodents following oral and instrumental administration. J Pathol 139:105–114PubMedCrossRefGoogle Scholar
  13. 13.
    Nwokolo CU, Gavey CJ, Smith JTL, Pounder RE (1989) The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate. Aliment Pharmacol Therap 3:29–39CrossRefGoogle Scholar
  14. 14.
    Slomiany BL, Nishikawa H, Bilski J, Slomiany A (1990) Colloidal bismuth subcitrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro. Am J Gastroenterol 390–393Google Scholar
  15. 15.
    Shorrock CJ, Crampton JR, Gibbons LC, Rees WDW (1989) Effect of bismuth subcitrate on amphibian gastroduodenal bicarbonate secretion. Gut 30:917–921PubMedCrossRefGoogle Scholar
  16. 16.
    Nihus M, Schieffer S, Malfertheiner P (1991) Inhibition of H. pylori adhesion to human SMC by CBS and different proteases. Irish J Med Sci 161 [Suppl 10]: 10Google Scholar
  17. 17.
    Alstead S (1941) Action of bismth carbonate in gastric disease. Lancet 11:420–423CrossRefGoogle Scholar
  18. 18.
    Bateson PR (1958) A comparative in vitro evaluation of a new bismuth salt bismuth aluminate. J Pharm Pharmacol 10:123–131PubMedCrossRefGoogle Scholar
  19. 19.
    Matts SGF, Swan CHJ, Kelleher J (1965) Double blind trial of bismuth aluminate and magnesium trisilicate in peptic ulceration with simultaneous gastric analysis. BMJ 1:753–756PubMedCrossRefGoogle Scholar
  20. 20.
    Marshall BJ, Armstrong JA, Francis GJ, Noke NT, Wee SH (1987) Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 27 [Suppl 2]: 16–30CrossRefGoogle Scholar
  21. 21.
    Vogt K, Warrelmann M, Hahn H (1989) The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori. Zbl Bakt 271:304–310Google Scholar
  22. 22.
    Goodwin CS, Blake P, Blincow E (1986) The minimum inhibitory and bactericidal concentrations of antibiotics and antiulcer agents against Campylobacter pyloridis. J Antimicrob Chemother 17:309–314PubMedCrossRefGoogle Scholar
  23. 23.
    Nilius M, Ströhle A, Espenhain E, Bode G, Malfertheiner P (1990) Coccoid like forms (CLF) of Helicobacter pylori - enzyme activity and antigenicity. Rev Esp Enf Digest 78[Suppl 1]: 28Google Scholar
  24. 24.
    Nilius M, Pugliese M, Malfertheiner P (1992) Electrophoretic characterization and inhibition of H. pylori catalase. Irish J Med Sci 161 [Suppl 10]: 51Google Scholar
  25. 25.
    Roine et al (1992) Colloidal bismuth subcitrate is a potent inhibitor of Helicobacter pylori associated alcohol dehydrogenase activity. Irish J Med Sci 161 [Suppl 10]: 47Google Scholar
  26. 26.
    Slomiany BL, Nishikawa H, Bilski J, Slomiany A (1990) Colloidal bismuth subcitrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro. Am J Gastroenterol 85:390–393PubMedGoogle Scholar
  27. 27.
    Sox T, Olson CHA (1989) Binding and killing of bacteria by bismuth subsalicylate. Antimicrob Agents Chemother 33:2075–2082PubMedGoogle Scholar
  28. 28.
    Goodwin CS, Armstrong JA, Cooper M (1991) Colloidal bismuth subcitrate inhibits the adherence of H. pylori to epithelial cells. Ital J Gastroenterol 23 [Suppl 2]: 40Google Scholar
  29. 29.
    Van Caekenberghe DL, Breyssens J (1987) In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother 31:1429–1430PubMedGoogle Scholar
  30. 30.
    McNulty CAM, Gearty JC, Crump B, Davis M, Donovan IA, Melikian V, Lister DM, Wise R (1987) Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. BMJ 293:645CrossRefGoogle Scholar
  31. 31.
    Tytgat GN, Rauws JE, Langenberg W (1986) The role of colloidal bismuth subcitrate in gastric ulcr and gastritis. Scand J Gastroenterol 21 [Suppl 122]: 22CrossRefGoogle Scholar
  32. 32.
    Marshall BJ, Armstrong JA, Graham J, Francis GJ, Nokes NT, Wee SH (1987) Antibacterial Action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 37 [Suppl 2]: 1630Google Scholar
  33. 33.
    Stanescu A, Malfertheiner P, Mayer D, Baczako K, Ditschuneit H (1989) Wismutsubnitrat - Therapie der Campylobacter-pylori-positiven chronischen erosiven Gastritis. Gastro-Entero- Hepatol 7:3Google Scholar
  34. 34.
    Stanescu A, Malfertheiner P, Mayer D, Baczako K, Ditschuneit H (1989) Wismutaluminat in der Gastroenterologie. Therapieeffekte bei chronischer erosiver Campylobacter-pylori-assoziierter Gastritis. Fortschr Med 107:623PubMedGoogle Scholar
  35. 35.
    McNulty CAM, Dent J, Wise R (1985) Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother 28:837–838PubMedGoogle Scholar
  36. 36.
    Glupczynski Y, Thibaumont F (1989) Comparative in vitro susceptibihty of Campylobacter pylori to different bismuth salts (abstract). Klin Wochenschr 67 [Suppl 18]: 24Google Scholar
  37. 37.
    Martin DF, Hollanders D, May SJ, Tweedle DEF, Ravenscroft MM, Miller JP (1981) Lancet 1:7–10PubMedCrossRefGoogle Scholar
  38. 38.
    Tytgat GNJ (1987) Colloidal bismuth subcitrate in peptic ulcer - a review. Digestion 37 [Suppl 2]: 31–41PubMedCrossRefGoogle Scholar
  39. 39.
    Bianchi-Porro B, Lazzaroni M, Parente F, Peprillo M (1986) The influence of colloidal bismuth subcitrate on duodenal ulcer relapse. Scand J Gastroenterol 21 [Suppl 122]: 36–38Google Scholar
  40. 40.
    Dobrilla G, Vallaperta P, Amplatz S (1988) Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment; a pooled estimate of controlled clinical trials. Gut 29:181–187PubMedCrossRefGoogle Scholar
  41. 41.
    Coghlan IG, Tobin A, O’Morain C (1989) Campylobacter pylori and ulcer treatment. In: Rathbone BJ, Heathley RV (eds) C. pylori and gastroduodenal disease. Blackwell Scientific Publications, Oxford, pp 232–245Google Scholar
  42. 42.
    Rauws EA, Tytgat GNJ (1990) Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335:1233–1235PubMedCrossRefGoogle Scholar
  43. 43.
    Marshall BJ, Warren JR, Blincow ED, PhilHps M, Goodwin CS, Murray R, Blackbourn SJ, Waters TE, Sanderson CR (1988) Prospective double-bhnd trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet II: 1437–1442CrossRefGoogle Scholar
  44. 44.
    Axon ATR (1991) Helicobacter pylori therapy: effect on peptic ulcer disease. J Gastroent Hepatol 6:131–132CrossRefGoogle Scholar
  45. 45.
    Borody T, Cole P, Noonan S et al. (1988) Long-term Campylobacter pylori recurrence post- eradication. Gastroenterology 94: A43Google Scholar
  46. 46.
    McNulty CAM, Gearty JC, Crump B, Davis M, Donovan IA, Mehkian V et al. (1986) Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. BJM 293:645–649CrossRefGoogle Scholar
  47. 47.
    Malfertheiner P, Stanescu A, Baczako K, Bode G, Ditschuneit H (1988) Chronic erosive gastritis - a therapeutic approach with bismuth. Scand J Gastroenterol 23 [SuppI142]: 87–92CrossRefGoogle Scholar
  48. 48.
    Marshall BJ, Dye KR, Plankey M, Frierson HF, Hoffman SR, Guerrant RL, McCallum RW (1988) Eradication of Campylobacter pylori infection with bismuth subsalicylate and antibiotic combinations. Am J Gastroenterol 83: 1035Google Scholar
  49. 49.
    Malfertheiner P, Stanescu A, Lehnhardt G, Bode G, Kemmer TP, Ditschuneit H (1990) In vivo and in vitro susceptibility of Helicobacter pylori. Gastroenterology 98: A82Google Scholar
  50. 50.
    Leehat P, Kisch R (1986) Bismuth induced encephalopathies: reappraisal of risks. Gastroenterol. Clinbiol 10:562–569Google Scholar
  51. 51.
    Hasking GJ, Duggan JM (1982) Encephalopathy from bismuth subsalicylate. Med J Austr 2: 167Google Scholar
  52. 52.
    Martin-Bouyer G, Foulon B, Guerbois, H, Barrin C (1980) Aspects epidemiologiques des encephalopathies apres administration de bismuth par voie orale. Therapie 35: 307–313PubMedGoogle Scholar
  53. 53.
    Czerwinski AW, Ginn HE (1964) Bismuth nephrotoxity. Am J Med 37:969–975PubMedCrossRefGoogle Scholar
  54. 54.
    Winship KA (1983) Toxicity of bismuth salts. Adv Drug Ract Ac Pois Rev 2: 103–121Google Scholar
  55. 55.
    Urizar R, Vernier RL (1966) Bismuth nephropathy. JAMA 198:207–209CrossRefGoogle Scholar
  56. 56.
    Gaueher A, Netter P, Faure G, Hutin MF, Burnel D (1979) Bismuth-induced osteoarthropathies. Med JAust 1: 129–130Google Scholar
  57. 57.
    Hudson M, Mowat NAG (1989) CBS (De-Nol) self-poisoning-reversible toxicity. BJ 299: 159Google Scholar
  58. 58.
    Karelitz S, Freedman AD (1951) Hepatitis and nephrosisdue to soluble bismuth. Pediatrics 8:772–777PubMedGoogle Scholar
  59. 59.
    Peters EE (1942) Bismuth stomatitis and albumin uria report of 6 cases. Am J Syph Gonnorhea Vener Dis 26:84–95Google Scholar
  60. 60.
    Silverman SS (1944) Bismuth stomatitis during the treatment of syphilis in the axury. Mil Surg 95:486–489Google Scholar
  61. 61.
    Goldman L, Clarke GE (1939) Erythema of ninth day syndrome associated with bismuth therapy. Am J Syph Gonorrhea Vener Dis 23: 224–227Google Scholar
  62. 62.
    Dobes WL, Aiden HS (1949) Pityriasis rosea-like drug cruptions due to bismuth. South Med J 42: 572–579PubMedCrossRefGoogle Scholar
  63. 63.
    Heyman A (1944) Systemic manifestations of bismuth toxicity observations on 4 patients with preexistent kidney disease. Am J Syph Gonorrhea Vener Dis 28: 721–732Google Scholar
  64. 64.
    Emile J de Bray JM, Vernat M, Morer T, Allain P (1979) Le osteopathies scapulaires et vertebrales des encephalophaties aigues myocloniques bismuthiques. Apropos de 8 cas. Ann Med Intern 130:75Google Scholar
  65. 65.
    Hillemand P, Palliere M, Laquais B, Bouvet P (1977) Traitement bismuthique et bismuthernie Semaine des Hopiteaux de Paris 53: 1663–1669Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • P. Malfertheiner
    • 1
  • M. Nilius
    • 1
  • U. Kreusel
    • 2
  1. 1.Department of Internal Medicine IUniversity of UlmUlmGermany
  2. 2.Department of Inorganic ChemistryTechnical University of MunichGermany

Personalised recommendations